Skip to main content
SpringerLink
Log in

Basiliximab cost effective after renal transplant

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014-2015 British pounds

Reference

  • Snowsill TM, et al. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation. Nephrology Dialysis Transplantation 32: 1251-1259, No. 7, Jul 2017. Available from: URL: http://doi.org/10.1093/ndt/gfx074

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Basiliximab cost effective after renal transplant. PharmacoEcon Outcomes News 787, 8 (2017). https://doi.org/10.1007/s40274-017-4336-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4336-6

Search

Navigation